Method for sterilizing sterile liquid pharmaceutical formulation comprising enxetine

Through dry heat sterilization technology, encifantine particles are heated at 100°C to 220°C and combined with sterile liquid carriers, the problem of difficult sterilization of encifantine particles liquid pharmaceutical compositions in the prior art is solved, and the problem of sterilization of encifantine particles is realized. Production of sterile liquid pharmaceutical compositions that are sterile and pharmaceutically stable.

CN118946344APending Publication Date: 2024-11-12VERONA PHARMA
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202380021600.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-21
Filing Date
2023-02-20
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

There are no suitable methods for sterilizing liquid pharmaceutical compositions containing encifantine particles, prior art such as final sterilization or dry gamma ray sterilization can lead to degradation of the formulation, making it difficult to meet sterility and drug stability. Requirements.

Method used

Using dry heat sterilization technology, encifantine particles are heated at a temperature of 100°C to 220°C to obtain sterile particles, and then combined with sterile liquid carriers to produce sterile liquid pharmaceutical compositions suitable for administration by inhalation. The final sterilization step is avoided to prevent the introduction of impurities.

Benefits of technology

Achieve high-efficiency dry-heat sterilization of sterile encifantine granules, ensuring the purity and stability of the drug, avoiding degradation problems, meeting the requirements of sterility and drug quality, and providing a suitable for inhalation administration. Bacterial liquid pharmaceutical composition.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004990852740000011
    Figure BDA0004990852740000011
  • Figure BDA0004990852740000081
    Figure BDA0004990852740000081
  • Figure BDA0004990852740000091
    Figure BDA0004990852740000091
Patent Text Reader

Abstract

The present invention relates to a process for the production of a sterile liquid pharmaceutical composition suitable for inhalation administration comprising enxetine particles, the process comprising: (a) heating the enxetine particles at a temperature of 100 DEG C to 220 DEG C to obtain sterile enxetine particles; and (b) combining the sterile enxetine particles with a sterile liquid solvent to produce a sterile liquid pharmaceutical composition suitable for inhalation administration. A method of producing an ampoule comprising a sterile liquid pharmaceutical composition is also described.
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention relates to a process for producing a sterile formulation comprising an active pharmaceutical ingredient. Background of the Invention

[0003] Certain pharmaceutical products must meet stringent sterility standards before they can be used on patients. Given the importance of sterility for pharmaceutical products, a variety of different methods, protocols, and techniques have been developed to sterilize pharmaceutical products. These methods, protocols, and techniques include steam sterilization, dry heat sterilization, ionizing radiation sterilization (including X-ray and gamma ray sterilization), gas sterilization, sterile filtration, and aseptic processing. Selecting a sterilization protocol for a new pharmaceutical product is a complex process that relies on evaluating the various available methods and their suitability for that particular product.

[0004] Ensifentin (N-(2-{(2E)-9,10-dimethoxy-4-oxo-2-[(2,4,6-trimethylphenyl)imino]-6,7-dihydro-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl}ethyl)urea; also known as RPL554) is a dual PDE3 / PDE4 inhibitor and is described in WO 00 / 58308A1. Ensifentin has bronchodilatory and anti-inflammatory activities and can be used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The structure of Ensifentin is shown below.

[0005]

[0006] As described in WO 2016 / 042313 A1, Ensifentin can be formulated as a suspension of particles in a diluent.

[0007] Suitable methods for sterilizing liquid pharmaceutical compositions containing ensifentine particles have not been described. Therefore, there is a great need to develop methods for producing sterile ensifentine suspensions. SUMMARY OF THE INVENTION

[0009] The inventors have found that of all available sterilization techniques, dry heat sterilization of active agent particles followed by aseptic compounding is particularly suitable for formulating Ensifentin as a suspension. Other techniques such as terminal sterilization or dry gamma ray sterilization have been found to result in degradation of the formulation.

[0010] Therefore, the present invention provides a method for producing a sterile liquid pharmaceutical composition suitable for administration by inhalation comprising ensifentine particles, the method comprising: (a) heating the ensifentine particles at a temperature of 100° C. to 220° C. to obtain sterile ensifentine particles; and (b) combining the sterile ensifentine particles with a sterile liquid carrier to produce the sterile liquid pharmaceutical composition suitable for administration by inhalation.

[0011] The present invention also provides a method for producing an ampoule containing a sterile liquid pharmaceutical composition suitable for administration by inhalation, the method comprising: (i) producing a sterile liquid pharmaceutical composition suitable for administration by inhalation containing ensifentin particles by the method defined herein; and (ii) filling an ampoule with the sterile liquid pharmaceutical composition suitable for administration by inhalation. DETAILED DESCRIPTION OF THE INVENTION

[0013] The method of the present invention produces a sterile liquid pharmaceutical composition. The sterile liquid pharmaceutical composition is suitable for administration by inhalation. The sterile liquid pharmaceutical composition comprises sterile ensifentin particles.

[0014] The term "sterile" refers to a composition that is substantially free of living microorganisms. Thus, a sterile composition is typically one that is substantially free of living bacteria or fungi. The term "sterile" is well known in the art.

[0015] Sterile liquid pharmaceutical compositions may have a sterility assurance level (SAL) less than or equal to 10 -3 , less than or equal to 10 -6 or less than or equal to 10 -9 For example, SAL is 10 -6 This means that the probability that the final product is non-sterile is 1 / 10 6 The sterile liquid pharmaceutical composition may have a total bioburden limit of less than or equal to 10 CFU / mL, or less than or equal to 1 CFU / mL. "CFU" is colony forming unit. The bioburden may be used in accordance with USP 31 <61> Measured by a plate count method as described in, for example, the pour plate method.

[0016] Typically, the sterility of liquid pharmaceutical compositions is determined according to USP <71> or Ph Eur 2.6.1. Liquid pharmaceutical compositions are usually required to comply with USP <71> Or the acceptance criteria defined in Ph Eur 2.6.1.

[0017] The pharmaceutical composition is a liquid pharmaceutical composition, and is therefore liquid at room temperature conditions (eg at a temperature of 10 to 40°C).

[0018] The sterile liquid pharmaceutical composition comprises sterile ensifentin particles. The ensifentin particles comprise ensifentin (i.e., ensifentin free base) or a pharmaceutically acceptable salt thereof. Typically, the ensifentin particles comprise ensifentin free base. The ensifentin particles typically comprise at least 90.0% by weight ensifentin or a pharmaceutically acceptable salt thereof, preferably at least 95.0% by weight. The ensifentin particles may consist essentially of ensifentin or a pharmaceutically acceptable salt thereof, or consist of ensifentin or a pharmaceutically acceptable salt thereof. For example, the ensifentin particles may consist of ensifentin free base.

[0019] A composition consisting essentially of a component includes only that component and other components that do not materially affect the basic properties of that component. A composition consisting essentially of a component typically includes at least 99.5% by weight of that component relative to the total weight of the composition.

[0020] The sterile ensifentin particles in the sterile liquid pharmaceutical composition may be suspended in a sterile liquid carrier. Thus, the sterile liquid pharmaceutical composition typically comprises a suspension of ensifentin particles. It is also possible that some or all of the ensifentin particles in the sterile liquid pharmaceutical composition have settled to the bottom of the container containing the sterile liquid pharmaceutical composition, for example after storage for a period of time. The ensifentin particles may be resuspended by any suitable means, such as by stirring the sterile liquid pharmaceutical composition.

[0021] Step (a) of the method typically comprises heating the ensifentin particles at a temperature of 120° C. to 200° C. The method may comprise heating the ensifentin particles at a temperature of 140° C. to 180° C., for example 150° C. to 170° C. or 155° C. to 165° C.

[0022] The ensifentin particles may be heated for any period of time suitable for producing sterile ensifentin particles. The method generally comprises heating the ensifentin particles at the temperature for 10 minutes to 24 hours. The method may comprise heating the ensifentin particles at the temperature for 30 minutes to 360 minutes, such as 45 minutes to 160 minutes or 60 minutes to 140 minutes.

[0023] The method preferably comprises heating the ensifentin particles at a temperature of 145° C. to 175° C. for 45 to 160 minutes. For example, the method may comprise heating the ensifentin particles at a temperature of 155° C. to 165° C. for 110 to 130 minutes.

[0024] Heating the Ensifentin particles for a certain time within a specific temperature range means the total time that the temperature of the Ensifentin particles is kept within the temperature range. The Ensifentin particles are usually heated for the relevant time in a single heating step, but the heating can also be performed in two or more steps. For example, heating at a temperature of 140°C to 180°C for 60 minutes may include a single heating step lasting 60 minutes or two heating steps lasting 30 minutes each. Generally, the Ensifentin particles are heated for a certain time in a single heating step at a specific temperature.

[0025] Step (a) is typically a dry heat sterilization process. The Ensifentin particles are typically in the form of a dry powder. Thus, the method may include heating a dry powder comprising the Ensifentin particles at a temperature of 100°C to 220°C to obtain a sterile dry powder comprising the Ensifentin particles. Typically, the Ensifentin particles are dry heat treated alone. The method may include heating a dry powder of the Ensifentin particles (i.e., a dry powder consisting essentially of the Ensifentin particles) at a temperature of 100°C to 220°C to obtain a sterile dry powder of the Ensifentin particles. The dry powder is typically a powder having a moisture content of less than 5.0% by weight, less than 1.0% by weight, or less than 0.1% by weight.

[0026] The ensifentin particles typically have a particle size distribution with a Dv50 of 0.5 μm to 5.0 μm. The ensifentin particles preferably have a Dv50 of 1.0 μm to 2.0 μm. Typically, the ensifentin particles have a Dv10 of 0.2 μm to 1.0 μm and a Dv90 of 2.5 μm to 6.0 μm. For example, the ensifentin particles may have a Dv10 of 0.4 μm to 0.6 μm and a Dv90 of 2.8 μm to 4.2 μm.

[0027] Particle size is described herein by the Dv50 value, which is the median particle size of the volume distribution. Thus, half of the volume of particles have a diameter less than the Dv50 value, and half of the volume of particles have a diameter greater than the Dv50 value. This is a common way to describe particle size distribution. The Dv10 and Dv90 parameters can also be used to characterize the particle size distribution of a sample. 10% of the volume of particles have a diameter less than the Dv10 value. 90% of the volume of particles have a diameter less than the Dv90 value.

[0028] The technique used to measure the Dv50 (and Dv10 and Dv90) values ​​described herein is typically laser diffraction. The particle size distribution of the ensifentin particles can be measured by laser diffraction using a wet powder dispersion system. For example, the particle size distribution can be measured using a Malvern Spraytec in combination with a wet dispersion cell for laser diffraction. Typically, the instrument parameters for the Malvern Spraytec are as follows:

[0029] · Grains – standard opaque granules;

[0030] · Refractive index of particles -1.50;

[0031] Refractive index (imaginary part) -0.50;

[0032] Particle density - 1.00;

[0033] Dispersant refractive index -1.33;

[0034] Controller unit - 1000RPM;

[0035] Measurement type – timing;

[0036] Initial sampling time – 30 seconds;

[0037] · Shading degree - 20% to 30%;

[0038] • Dispersant - 1% Polysorbate 20 in deionized water.

[0039] Ensifentin particles can be produced by any pharmaceutically acceptable particle size reduction method or particle size control production method. For example, particles can be produced by spray drying an ensifentin solution, controlled crystallization, or by reducing the particle size of an ensifentin solid form (e.g., by jet milling, mechanical micronization, or media milling).

[0040] The method further comprises combining the sterile ensifentine particles with a sterile liquid carrier to produce a sterile liquid pharmaceutical composition suitable for administration by inhalation. Combining the sterile ensifentine particles with a sterile liquid carrier generally comprises mixing the sterile ensifentine particles with a sterile liquid carrier.

[0041] The sterile liquid carrier typically includes one or more diluents. The diluent can be any suitable liquid diluent. For example, the sterile liquid carrier typically includes a diluent, which is water. The sterile liquid carrier can include one or more other diluents, or the sterile liquid carrier can include a single diluent. The sterile liquid carrier can include a single diluent, which is water.

[0042] A sterile liquid carrier comprising water can be used to produce a sterile liquid pharmaceutical composition suitable for use in a nebulizer. The sterile liquid carrier generally also includes one or more other excipients selected from surfactants, buffers and osmotic pressure regulators.

[0043] The sterile liquid carrier also typically contains an osmotic pressure regulator. Examples of osmotic pressure regulators include sodium chloride, potassium chloride, glucose, glycerol and mannitol. Preferably, the osmotic pressure regulator is sodium chloride.

[0044] The concentration of the osmotic pressure regulator in the sterile liquid carrier is generally greater than or equal to 1.0 mg / mL (e.g., 1.0 to 50.0 mg / mL). Preferably, the concentration of the osmotic pressure regulator is 4.0 to 20.0 mg / mL or 6.0 to 12.0 mg / mL.

[0045] The sterile liquid carrier also generally comprises one or more surfactants. The one or more surfactants may include nonionic surfactants, anionic surfactants, cationic surfactants, zwitterionic surfactants or mixtures thereof. Generally, the one or more surfactants comprise nonionic surfactants.

[0046] Examples of surfactants include lecithin, oleic acid, polyoxyethylene alkyl ethers (e.g., PEG 300, PEG 600, PEG 1000, Brij 30, Brij 35, Brij 56, Brij 76, and Brij 97), polypropylene glycol (e.g., PPG 2000), glucoside alkyl ethers, octylphenol polyoxyethylene ethers, polyoxyethylene alkylphenol ethers, glycerol alkyl esters, polyoxyethylene sorbitan alkyl esters (e.g., polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80), sorbitan alkyl esters (e.g., sorbitan monolaurate (Span 20), sorbitan monooleate (Span 80), and sorbitan trioleate (Span 85)), cocamide MEA, cocamide DEA, dodecyldimethylamine oxide, block copolymers of polyethylene glycol and polypropylene glycol (poloxamers), block copolymers of polyethylene glycol and polypropylene glycol oxide (e.g., pluronic surfactants), polyvinyl pyrrolidone K25, polyvinyl alcohol, oligolactic acid, sodium bisoctylsulfosuccinate, and polyethoxylated tallow amine (POEA).

[0047] Preferably, the one or more surfactants include polysorbates and / or sorbitol alkyl esters. The one or more surfactants may, for example, include polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate) or polysorbate 80 (polyoxyethylene (20) sorbitan monooleate). The one or more surfactants may, for example, include sorbitan monolaurate (Span 20), sorbitan monooleate (Span 80) or sorbitan trioleate (Span 85). Preferably, the sterile liquid carrier includes polysorbate 20 and / or sorbitan monolaurate (Span 20).

[0048] The sterile liquid carrier can include two or more surfactants, or the sterile liquid carrier can include a single surfactant. For example, the composition can include a single surfactant, and the single surfactant is a polysorbate, such as polysorbate 20. The sterile liquid carrier can include two or more surfactants. For example, the sterile liquid carrier can include polysorbate 20 and sorbitan monolaurate (Span 20).

[0049] The total concentration of one or more surfactants in the sterile liquid carrier is generally 0.01 to 2.0 mg / mL. Preferably, the total surfactant concentration is 0.1 to 1.0 mg / mL. For example, the total surfactant concentration in the sterile liquid carrier can be 0.25 to 0.75 mg / mL. The sterile liquid carrier can, for example, contain polysorbates at a concentration of 0.1 to 1.0 mg / mL, and optionally contain sorbitol alkyl esters at a concentration of 0.01 to 0.1 mg / mL.

[0050] The sterile liquid carrier also typically includes one or more buffers. Buffers can be used to control the pH of the liquid pharmaceutical composition. Buffers typically include weak acids and their conjugate bases. Examples of buffers include citrate buffers, phosphate buffers, acetate buffers, and bicarbonate buffers.

[0051] Preferably, the buffer is a phosphate buffer. For example, the sterile liquid carrier may contain sodium dihydrogen phosphate dihydrate and / or disodium hydrogen phosphate dihydrate.

[0052] The pH of the sterile liquid carrier is typically 6.0 to 7.5, such as 6.2 to 7.2. The pH of the sterile liquid carrier may be 6.5 to 6.9. The pH of the sterile liquid carrier is typically measured at 20°C. The pH of the sterile liquid carrier may be measured by any suitable technique. For example, a potentiometric pH meter may be used to measure the pH.

[0053] The total concentration of one or more buffers in the sterile liquid carrier is typically 0.1 to 20.0 mg / mL. Preferably, the buffer concentration is 1.0 to 2.0 mg / mL. The concentration of the buffer includes the acid and conjugate base components of the buffer.

[0054] Typically, the sterile liquid carrier includes: water, one or more osmotic pressure regulators, one or more buffers and one or more surfactants. The sterile liquid carrier may, for example, include: water, sodium chloride, sodium dihydrogen phosphate dihydrate, disodium hydrogen phosphate dihydrate, polysorbate 20 and sorbitan laurate.

[0055] The method generally also includes producing a sterile liquid carrier. A sterile liquid carrier can be produced by sterilizing the liquid carrier, for example by heat treatment or gamma ray treatment of the liquid carrier. A sterile liquid carrier is generally produced by sterile filtration of the liquid carrier. Sterile filtration generally includes filtering the liquid carrier through a filter having a pore size not greater than 0.5 μm or not greater than 0.3 μm (e.g., about 0.2 μm).

[0056] The method of the present invention produces a sterile liquid pharmaceutical composition by aseptic processing and compounding. Therefore, the method generally does not further include a terminal sterilization step (which has been found to introduce impurities into the composition). For example, the method generally does not further include heating the sterile liquid pharmaceutical composition suitable for administration by inhalation containing the ensifentin particles at 100°C or higher.

[0057] The concentration of the ensifentin particles in the sterile liquid pharmaceutical composition produced by the method can be any suitable concentration, for example 0.01 to 400 mg / mL. Typically, the concentration of the ensifentin particles is 0.1 to 5.0 mg / mL. Preferably, the concentration of the ensifentin particles is 0.1 to 2.5 mg / mL. For example, the concentration of the ensifentin particles can be 0.15 to 0.5 mg / mL or 1.0 to 2.0 mg / mL.

[0058] For example, a sterile liquid pharmaceutical composition may include:

[0059] ·water;

[0060] particles composed of ensifentine free base at a concentration of 0.1 to 20 mg / mL;

[0061] One or more osmotic pressure regulating agents at a total concentration of 1.0 to 15 mg / mL;

[0062] One or more buffers at a total concentration of 0.1 to 4 mg / mL; and

[0063] • One or more surfactants at a total concentration of 0.05 to 3 mg / mL.

[0064] Sterile liquid pharmaceutical compositions may include:

[0065] ·water;

[0066] particles composed of ensifentine free base at a concentration of 0.5 to 6 mg / mL;

[0067] Sodium chloride at a concentration of 5 to 12 mg / mL;

[0068] Sodium dihydrogen phosphate dihydrate at a concentration of 0.3 to 2 mg / mL;

[0069] Sodium phosphate dihydrate at a concentration of 0.3 to 2 mg / mL;

[0070] Polysorbate 20 at a concentration of 0.1 to 1.5 mg / mL; and

[0071] • Sorbitan laurate at a concentration of 0.01 to 0.5 mg / mL.

[0072] The present invention also provides a method for producing an ampoule containing a sterile liquid pharmaceutical composition suitable for administration by inhalation. The method comprises: (i) producing a sterile liquid pharmaceutical composition suitable for administration by inhalation containing ensifentin particles by the method defined herein; and (ii) filling an ampoule with the sterile liquid pharmaceutical composition suitable for administration by inhalation. The ampoule may be a glass ampoule or a plastic ampoule. The ampoule is typically a polyethylene plastic ampoule. After filling, the ampoules may be wrapped in aluminum foil bags respectively.

[0073] The ampoule may be a blow-fill-seal ampoule. For example, the method may be a method of producing an ampoule using blow-fill-seal technology, the ampoule containing a sterile liquid pharmaceutical composition suitable for administration by inhalation, the method comprising: (i) producing a sterile liquid pharmaceutical composition suitable for administration by inhalation containing ensifentin particles by a method defined herein; and (ii) producing a blow-fill-seal ampoule filled with a sterile liquid pharmaceutical composition suitable for administration by inhalation. Example

[0074] method

[0075] Secondary analytical testing was performed using the key high performance liquid chromatography (HPLC) parameters shown in Table 1.

[0076]

[0077]

[0078] Impurity determinations were performed twice using the key HPLC parameters shown in Table 2.

[0079]

[0080] Tested Products

[0081] The effects of different sterilization techniques were evaluated for the following products:

[0082] (i) a suspension formulation comprising ensifentine particles (terminally sterilized); and

[0083] (ii) Ensifentin granules before formulation into suspension (sterile compounding and filling).

[0084] Three aqueous suspensions having the formulations shown in Tables 3 to 5 were prepared.

[0085]

[0086]

[0087]

[0088]

[0089] Unformulated ensifentin granules were evaluated in dry powder form.

[0090] Sterilization technology

[0091] The sterilization techniques shown in Table 6 were evaluated.

[0092]

[0093] The sterile micronized ensifentin obtained by techniques C to F can then be combined with a sterile carrier to obtain a suspension formulation.

[0094] result

[0095] The content and related substances of the products obtained by each sterilization technique from A to F were evaluated by the HPLC method described above. The results are summarized in Table 7.

[0096]

[0097] in conclusion

[0098] The results in Table 7 indicate that final heat treatment (Technique A), final gamma irradiation (Technique B), and dry gamma irradiation (Technique F) caused some degradation when used to prepare sterile suspensions of ensifentin particles.

[0099] However, it was found that the Ensifentin particles were highly resistant to dry heat sterilization, with no significant change in purity or content after treatment at temperatures between 150° C. and 170° C. Preferably, the dry heat treatment was performed at 160° C. for at least 120 minutes. The sterilized Ensifentin particles obtained by dry heat treatment can be combined with a suspension carrier in aseptic compounding and processing to obtain a sterile suspension preparation containing Ensifentin.

Claims

1. A method for producing a sterile liquid pharmaceutical composition comprising ensifentine particles suitable for administration by inhalation, wherein the method comprises: (a) heating the ensifentin particles at a temperature of 100° C. to 220° C. to obtain sterile ensifentin particles; as well as (b) combining the sterile Ensifentin particles with a sterile liquid carrier to produce the sterile liquid pharmaceutical composition suitable for administration by inhalation.

2. The method of claim 1, wherein the method comprises heating the ensifentin particles at a temperature of 120°C to 200°C.

3. The method of claim 1 or claim 2, wherein the method comprises heating the ensifentin particles at a temperature of 140°C to 180°C.

4. A method according to any preceding claim, wherein the method comprises heating the ensifentin particles at the temperature for a period of 10 minutes to 24 hours.

5. A method as claimed in any preceding claim, wherein: The method comprises heating the ensifentin particles at the temperature for 30 minutes to 360 minutes.

6. A method according to any preceding claim, wherein the method comprises heating the ensifentin particles at a temperature of 145°C to 175°C for a period of 45 minutes to 160 minutes.

7. A method according to any preceding claim, wherein the method comprises heating the ensifentin particles at a temperature of 155°C to 165°C for a period of 110 minutes to 130 minutes.

8. The method according to any one of the preceding claims, wherein the ensifentin particles comprise at least 95% by weight of ensifentin or a pharmaceutically acceptable salt thereof relative to the total weight of the ensifentin particles.

9. The method of any preceding claim, wherein the ensifentin particles are in the form of a dry powder.

10. The method of any preceding claim, wherein the ensifentin particles have a particle size distribution of Dv50 of 0.5 to 5.0 microns.

11. A method as claimed in any preceding claim, wherein the sterile liquid carrier comprises a diluent and optionally one or more other excipients selected from a surfactant, a buffer and an osmotic pressure regulator.

12. A method as claimed in any preceding claim, wherein the sterile liquid carrier comprises a diluent which is water.

13. A method as claimed in any preceding claim, wherein the sterile liquid carrier comprises a single diluent which is water.

14. The method of claim 13, wherein the sterile liquid carrier comprises: Water, sodium chloride, sodium dihydrogen phosphate dihydrate, disodium hydrogen phosphate dihydrate, polysorbate 20 and sorbitan laurate.

15. A method according to any preceding claim, wherein the method further comprises producing the sterile liquid carrier by sterile filtration of the liquid carrier.

16. The method of any preceding claim, wherein the method does not further comprise heating the sterile liquid pharmaceutical composition suitable for administration by inhalation at a temperature of 100°C or higher.

17. A process for producing an ampoule containing a sterile liquid pharmaceutical composition suitable for administration by inhalation, the process comprising: (i) producing a sterile liquid pharmaceutical composition suitable for administration by inhalation comprising particles of Ensifentin by the process defined in any one of claims 1 to 16; and (ii) filling ampoules with the sterile liquid pharmaceutical composition suitable for administration by inhalation.

Citation Information

Cited By

  • Endafetine pharmaceutical composition as well as preparation method and application thereof

    CN122075406A

  • Compound pharmaceutical composition containing PDE-3 / 4 inhibitor, pharmaceutical preparation and preparation method and application thereof

    CN122424339A